|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 269.1 AUD | -0.85% |
|
-4.40% | -6.05% |
| Apr. 10 | Miners boost Australian shares; NZ cenbank keeps rates steady | RE |
| Apr. 10 | New Zealand shares hold gains as c.bank expectedly holds rate; Aussie shares up | RE |
Oct 14 (Reuters) - Australian biotech CSL said on Thursday it was committed to its manufacturing agreement of about 50 million doses with AstraZeneca's COVID-19 vaccine into 2022.
The announcement came after a media report said AstraZeneca's vaccine, Vaxzevria, will no longer be manufactured in Australia due to demand for vaccines of Pfizer and Moderna. (Reporting by Indranil Sarkar in Bengaluru)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 10,914 GBX | +0.48% | -0.44% | 211B | ||
| 102 USD | -1.39% | -4.68% | 39.05B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -6.05% | 84.46B | |
| +3.95% | 40.85B | |
| -26.37% | 27.69B | |
| +52.09% | 24.28B | |
| -6.59% | 17.09B | |
| -32.37% | 13.67B | |
| -10.45% | 11.79B | |
| -15.88% | 11.86B | |
| -2.85% | 8.07B | |
| +0.53% | 7.51B |
CSL LIMITED 
